In a recent issue of Clinical Science, Prieto-Vicente et al. [Clin. Sci. (2018) 132, 985–1001] have smartly demonstrated a potential new use of cardiotrophin-1 (CT-1) to treat and palliate an inflammatory bowel disease such as ulcerative colitis. In that work, authors report that in ulcerative colitic mice, administration of exogenous recombinant CT-1 (rCT-1) promotes lower colon damage and lower disease activity index, reducing systemic levels of tumor necrosis factor α (TNF-α) and also diminishing TNF-α expression in colon together with the reduction in other common inflammation markers. Besides, in vivo rCT-1 administration induces activation of several molecular pathways, including nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) and signal transducer and activator of transcription (STAT)-3, and abolishes bacterial translocation from intestine to other organs, including mesenteric ganglia, lungs, and spleen. Additionally, these results were nicely corroborated in CT-1 depleted mice; in which colon damage and ulcerative colitis severity were greater compared with the wild-type counterparts. All together, these results suggested that CT-1 could be a promising new therapeutic approach for treating inflammatory bowel disease, particularly ulcerative colitis. However, further studies are required to determine its major mechanisms of action and the potential efficacy of CT-1 in human inflammatory bowel diseases.
Skip Nav Destination
Article navigation
October 2018
-
Cover Image
Cover Image
In this issue, Wohlfahrtova et al. report on the link between early isolated v-lesion (eIV) and rejection of kidney allografts. The cover image is a Circos plot that depicts the association between the 15 most signifi cant up-regulated genes between TCMRV (T cell-mediated vascular rejection) and eIV, and signifi cantly enriched pathways and GO terms that play a role in the immune response. For further details, see pages 2269–2284 .
Commentary|
October 19 2018
Potential clinical treatment of colitis with cardiotrophin-1
Xavier Escoté
1University of Navarra, Department of Nutrition, Food Science and Physiology, Edificio de Investigación, C/Irunlarrea 1, Pamplona 31008, Spain
2University of Navarra, Centre for Nutrition Research, Faculty of Pharmacy and Nutrition, Edificio de Investigación, C/Irunlarrea 1, Pamplona 31008, Spain
Correspondence: Xavier Escoté ([email protected])
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
May 30 2018
Revision Received:
September 05 2018
Accepted:
September 26 2018
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2018 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society
2018
Clin Sci (Lond) (2018) 132 (20): 2169–2174.
Article history
Received:
May 30 2018
Revision Received:
September 05 2018
Accepted:
September 26 2018
Connected Content
This is a commentary on:
Cardiotrophin-1 attenuates experimental colitis in mice
Citation
Xavier Escoté; Potential clinical treatment of colitis with cardiotrophin-1. Clin Sci (Lond) 31 October 2018; 132 (20): 2169–2174. doi: https://doi.org/10.1042/CS20171626
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |